Related Experiment Videos
Dose-related physostigmine-induced ventricular arrhythmia: case report
The Journal of Clinical Psychiatry
|October 1, 1985
Summary
Physostigmine, a cholinesterase inhibitor, may treat dementia. However, intravenous physostigmine administration in an elderly patient induced cardiac arrhythmias, including premature contractions and bigeminy.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Physostigmine is investigated for treating primary degenerative dementia due to its action as a central cholinesterase inhibitor.
- Cholinesterase inhibitors are a known therapeutic class for managing cognitive decline in dementia.
Observation:
- An 85-year-old male patient was administered intravenous physostigmine.
- The patient's cardiac rhythm was monitored during the experimental administration.
Findings:
- Intravenous physostigmine administration resulted in the development of unifocal premature contractions.
- The patient also experienced runs of bigeminy following physostigmine administration.
Implications:
- This case highlights potential cardiac side effects of physostigmine, even when considered for neurological conditions.
- Careful cardiac monitoring may be necessary in patients receiving physostigmine, particularly the elderly.
- Further research is needed to understand the risk-benefit profile of physostigmine regarding cardiac safety in dementia patients.